Atrial Fibrillation Market is expected to reach US$ 20,925.79 million by 2028

North America to Account for Larger Share in Global Atrial Fibrillation Market During 2022–2028

The global atrial fibrillation market is expected to grow from US$ 9,511.05 million in 2022 to US$ 20,925.79 million by 2028; it is estimated to grow at a CAGR of 14.11% from 2022 to 2028. The report highlights the key factors driving the market growth and prominent players with their developments in the market. 

The US holds the largest share of the North American Atrial Fibrillation Market

The North America atrial fibrillation market has been segmented into the US, Canada, and Mexico. The growth of the atrial fibrillation market in the North America is determined due to factors such as by rising geriatric population, increasing occurrence of cardiovascular diseases, high accessibility to advanced technologies, growing development of innovative and technologically advanced products, and increasing healthcare expenditure. Collaborations and robust R&D activities has also led to stimulate the growth of the market. Among the North American countries, US holds the largest share of the North American atrial fibrillation market. The country has a presence of a vast population suffering with several diseases. According to the Centers for Disease Control and Prevention (CDC), over 750,000 hospitalizations occur each year because of AFib and the condition contributes to ~130,000 deaths each year in the US. Therefore, the high prevalence of the disease that require AFib medication and surgery, which is anticipated to be responsible for the atrial fibrillation market surge in the coming years. In addition, the market players are also focused towards offering innovative products to sustain in the highly competitive global market scenario. For instance, in December 2019, US FDA approved the drug from Micro Labs Ltd. and Mylan Pharmaceutical’s first generic drug of apixaban (Eliquis—Bristol-Myers Squibb) tablets to lower the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. Thus, the launch of novel products is likely to support the market growth in the coming years.

Global Atrial Fibrillation Market, by Region, 2022 (%)

Based on treatment type, the atrial fibrillation market is segmented into non-pharmacological and pharmacological. The non-pharmacological segment held a larger share of the market in 2022, and it is anticipated to register a higher CAGR during 2022–2028. The non-pharmacological segment is further divided into the surgical maze, catheter ablation, and electric cardioversion. In 2022, the MAZE surgery segment held the largest share of the market. However, the catheter ablation segment is estimated to register the highest CAGR in the market during the forecast period.

Based on end user, the atrial fibrillation market is segmented into hospitals, ambulatory surgical centers and cardiac catheterization laboratories. The hospitals segment accounted for the largest market share in 2021, and it is estimated to register the highest CAGR during the forecast period.

Boston Scientific Corporation; Medtronic; AtriCure, Inc; Johnson & Johnson (Biosense Webster, Inc.); BOEHRINGER INGELHEIM GMBH; CardioFocus; Abbott; Sanofi; Biotronik, Inc.; and Bristol-Myers Squibb Company are among the leading companies operating in the global atrial fibrillation market. 

Various organic and inorganic strategies are adopted by companies operating in the global atrial fibrillation market. Organic strategies mainly include product launches and product approvals. Further, acquisitions, collaborations, and partnerships are among the inorganic growth strategies witnessed in the market. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players strengthen their customer base and expand their product portfolios.

A few of the significant developments by key players operating in the global atrial fibrillation market are listed below:

• In in 2022, UPOlife, Latvian healthtech company launched has developed a product, named UPOlife Wearable Biosensor Patch. It is solution that directly addresses the pandemic caused challenges and allow users to assess their heart health and wellness state remotely. Moreover, in the same year, UPOlife launched “Heart Health in a Box” Concept at Arab Health 2022. Under the initiative, the company will offer home heart health assessment, combining the medical as well as wellness screening.
• In January 2022, Peerbridge Health collaborated with Northwell Health to launch AFib Center of Excellence, pilot program to optimize treatment for atrial fibrillation patients and who are undiagnosed with obstructive sleep apnea at Lenox Hill Hospital, US. The focus of the pilot program is to help cardiology and sleep physicians to understand the critical link between the two conditions in a better way and provide quick and effective treatment for atrial fibrillation and obstructive sleep apnea.
• In January 2019, Medtronic plc. acquired EPIX Therapeutics, Inc. This acquisition is likely to expand the Medtronic cardiac ablation portfolio to offer physicians a comprehensive set of tools to treat patients with cardiac arrhythmias.
• In August 2019, AtriCure, Inc. completed the acquisition of SentreHEART, Inc. With this, the company is likely to increase its product portfolio in the atrial ablation field.

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com